Clinical Trials Logo

Treatment clinical trials

View clinical trials related to Treatment.

Filter by:

NCT ID: NCT05238662 Not yet recruiting - Treatment Clinical Trials

Novel Technique Lumber Spine Fusion: Unilateral Pedicular Screws Fixation Combined With Contralateral Interbody Cage

Start date: March 1, 2022
Phase: N/A
Study type: Interventional

● Null hypothesis (H0): Unilateral pedicle screw with contralateral interbody cage has better outcomes than unilateral pedicle screw fixation with ipsilateral cage. ● Alternative hypothesis (H1): Unilateral pedicle screw with contralateral interbody cage gives the same outcomes as unilateral pedicle screw fixation with ipsilateral cage.

NCT ID: NCT05214391 Recruiting - Clinical trials for Immune Thrombocytopenia

A Prospective, One-arm and Open Clinical Study of Zanubrutinib in the Treatment of Immune Thrombocytopenia

Start date: February 15, 2022
Phase: Phase 2
Study type: Interventional

To evaluate the safety and efficacy of zanubrutinib in the treatment of immune thrombocytopenia in 30 patients.

NCT ID: NCT05199909 Recruiting - Thrombocytopenia Clinical Trials

Safety and Efficacy of Zanubrutinib in the Treatment of Antiphospholipid Syndrome With Secondary Thrombocytopenia

Start date: January 25, 2022
Phase: Phase 2
Study type: Interventional

To evaluate the safety and efficacy of zanubrutinib in the treatment of antiphospholipid syndrome with secondary thrombocytopenia in 10 patients.

NCT ID: NCT05160350 Completed - Epilepsy Clinical Trials

Probiotic in Treatment of Adult Patients With Drug-resistant Epilepsy

Start date: April 21, 2021
Phase: Phase 4
Study type: Interventional

This study is a randomized, double-blind parallel group placebo-controlled clinical trial with the aim of investigating the effect of probiotic versus placebo on drug-resistant adult patients with epilepsy.

NCT ID: NCT04948073 Completed - Low Back Pain Clinical Trials

The Effects of Dynamic Neuromuscular Stabilization Approach

Start date: June 24, 2021
Phase: N/A
Study type: Interventional

When the positive effects of the recently popular "Dynamic Neuromuscular Stabilization (DNS)" approach are examined, it suggests that it may be a possible treatment option in geriatric individuals with chronic nonspecific low back pain (CSNLP). Based on the principles of developmental kinesiology, the DNS approach takes advantage of infants' motor development curves in the treatment of motor disorders. The main focus is on regulating intra-abdominal pressure and the integrated spinal stabilizing system (ISSS) through specific functional exercises based on the positions exhibited by a healthy infant. According to the DNS, every developmental position is an exercise position, but every exercise must follow basic principles. These principles are restoration of correct respiratory pattern and intra-abdominal pressure, respectively; ensuring correct support during dynamic activities of the extremities and ensuring biomechanical alignment during movement. Considering the principles of exercise, there appears to be a potential mechanism of action for anomalies in geriatric individuals with CNSLBP. Therefore, in our study, we aimed to examine the effect of DNS approach on functional movement patterns, balance, quality of life and exercise capacity in geriatric individuals with CNSLBP. It is the first randomized controlled study in the literature, and our hypothesis is that the DNS approach may be an effective therapeutic approach on these parameters.

NCT ID: NCT04942002 Recruiting - Treatment Clinical Trials

Retrobulbar Methylprednisolone as Adjunctive Treatment in Optic Neuritis Trial

Start date: June 15, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

A double-blind prospective randomized clinical trial of treatment for optic neuritis comparing visual outcome of patients treated by standard therapy (intravenous methylprednisolone) + placebo injection and standard therapy + retrobulbar methylprednisolone.

NCT ID: NCT04838938 Completed - Treatment Clinical Trials

Personalized Medicine in Patients With Infective Endocarditis

Start date: March 1, 2021
Phase:
Study type: Observational [Patient Registry]

The hypothesis underlying this work is the identification of different sub phenotypes of patients with infective endocarditis through the study of the host's response to infection. Furthemore, metagenomic sequencing may be a helpful supplement to IE diagnostic, especially when conventional tests fail to yield a diagnosis.

NCT ID: NCT04699539 Recruiting - Treatment Clinical Trials

Different Patterns of Target Delineation in SBRT for Locally Advanced Pancreatic Cancer

Start date: March 31, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to compare the efficacy and safety of two target delineation methods in SBRT for LAPC, so as to determine whether the target delineation method based on recurrence pattern can obtain better survival benefits.

NCT ID: NCT04661228 Completed - Clinical trials for Substance Use Disorders

Diagnostic Survey of Mental and Substance Use Disorders in HUNT (PsykHUNT)

PsykHUNT
Start date: November 2, 2018
Phase:
Study type: Observational

The aims of this observational survey are to i) gather experience on how to conduct a prevalence study of mental disorders in the Norwegian setting, ii) collect data on the prevalence, risk factors and consequences of mental and substance use disorders, iii) collect data on treatment coverage for mental and substance use disorders, iv) conduct a thorough nonparticipation analysis.

NCT ID: NCT04627233 Not yet recruiting - Covid19 Clinical Trials

Ezrin Peptide (HEP-1) for Treatment of Coronavirus Disease (COVID-19) Infection

Start date: December 20, 2020
Phase: Phase 1
Study type: Interventional

Currently, SARS-CoV-2 the novel member of the corona virus family, affecting the world leading to COVID-19 disease. It can result life-threatening condition by developing severe acute respiratory distress syndrome (ARDS). Based on previous evidence a group of patients with severe COVID-19 develop a cytokine storm syndrome which leads to hyper-inflammation lung tissue damage. Supportive care is the current management of COVID-19 is and management of ARDS as a main cause of mortality has been remained challenging. Therefore, an urgent effective treatment of COVID-19 regarding hyper-inflammation mechanism is required. Currently, development of novel anti-viral agents and vaccines are the main issues. However, it needs long time, from months to years, until suitable new medications and vaccines have been developed. An immune-modulatory tetra deca peptide (14-mer peptide) named Human Ezrin Peptide 1 (HEP-1) (trade name Gepon) was introduced by the group of Ataullakhanov in Russia. Regarding its proved anti-viral and anti-inflammatory effect, Russian authorities approved Gepon for treatment of ulcerative colitis treatment and Hepatitis -C. In this regard, it seems that Hep-1 is a very safe immune-modulatory agent which can be effective in the management of COVID-19 infection without any adverse effect for the patient.